Literature DB >> 31948643

Incident Heart Failure and Long-Term Risk for Venous Thromboembolism.

Christina L Fanola1, Faye L Norby2, Amil M Shah3, Patricia P Chang4, Pamela L Lutsey2, Wayne D Rosamond4, Mary Cushman5, Aaron R Folsom2.   

Abstract

BACKGROUND: Heart failure (HF) hospitalization places patients at increased short-term risk for venous thromboembolism (VTE). Long-term risk for VTE associated with incident HF, HF subtypes, or structural heart disease is unknown.
OBJECTIVES: In the ARIC (Atherosclerosis Risk In Communities) cohort, VTE risk associated with incident HF, HF subtypes, and abnormal echocardiographic measures in the absence of clinical HF was assessed.
METHODS: During follow-up, ARIC identified incident HF and subcategorized HF with preserved ejection fraction or reduced ejection fraction. At the fifth clinical examination, echocardiography was performed. Physicians adjudicated incident VTE using hospital records. Adjusted Cox proportional hazards models were used to evaluate the association between HF or echocardiographic exposures and VTE.
RESULTS: Over a mean of 22 years in 13,728 subjects, of whom 2,696 (20%) developed incident HF, 729 subsequent VTE events were identified. HF was associated with increased long-term risk for VTE (adjusted hazard ratio: 3.13; 95% confidence interval: 2.58 to 3.80). In 7,588 subjects followed for a mean of 10 years, the risk for VTE was similar for HF with preserved ejection fraction (adjusted hazard ratio: 4.71; 95% CI: 2.94 to 7.52) and HF with reduced ejection fraction (adjusted hazard ratio: 5.53; 95% confidence interval: 3.42 to 8.94). In 5,438 subjects without HF followed for a mean of 3.5 years, left ventricular relative wall thickness and mean left ventricular wall thickness were independent predictors of VTE.
CONCLUSIONS: In this prospective population-based study, incident hospitalized HF (including both heart failure with preserved ejection fraction and reduced ejection fraction), as well as echocardiographic indicators of left ventricular remodeling, were associated with greatly increased risk for VTE, which persisted through long-term follow-up. Evidence-based strategies to prevent long-term VTE in patients with HF, beyond time of hospitalization, are needed.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  deep venous thrombosis; echocardiography; heart failure; pulmonary embolism; venous thromboembolism

Year:  2020        PMID: 31948643      PMCID: PMC7262575          DOI: 10.1016/j.jacc.2019.10.058

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Outcomes in adults with acute pulmonary embolism who are discharged from emergency departments: the Cardiovascular Research Network Venous Thromboembolism study.

Authors:  Margaret C Fang; Dongjie Fan; Sue Hee Sung; Daniel M Witt; Steven H Yale; Steven R Steinhubl; Alan S Go
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

Review 3.  Does heart failure confer a hypercoagulable state? Virchow's triad revisited.

Authors:  G Y Lip; C R Gibbs
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

4.  Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients.

Authors:  Eduardo S Darze; Adriana L Latado; Aloyra G Guimarães; Rodrigo A V Guedes; Alessandra B Santos; Simone S de Moura; Luiz Carlos Santana Passos
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

5.  Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.

Authors:  Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Joseph F Polak; Aaron R Folsom
Journal:  Arch Intern Med       Date:  2002-05-27

6.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

7.  Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.

Authors:  Faiez Zannad; Stefan D Anker; William M Byra; John G F Cleland; Min Fu; Mihai Gheorghiade; Carolyn S P Lam; Mandeep R Mehra; James D Neaton; Christopher C Nessel; Theodore E Spiro; Dirk J van Veldhuisen; Barry Greenberg
Journal:  N Engl J Med       Date:  2018-08-27       Impact factor: 91.245

8.  Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study).

Authors:  Laura R Loehr; Wayne D Rosamond; Patricia P Chang; Aaron R Folsom; Lloyd E Chambless
Journal:  Am J Cardiol       Date:  2008-02-14       Impact factor: 2.778

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.

Authors:  J G F Cleland; I Findlay; S Jafri; G Sutton; R Falk; C Bulpitt; C Prentice; I Ford; Adele Trainer; P A Poole-Wilson
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more
  9 in total

1.  A retrospective cohort study of disease-related risk factors for central venous catheter-related symptomatic thrombosis in intensive care unit inpatients.

Authors:  Zhiming Kuang; Xiaochun Liu; Yunlin Zhu; Hailiang Xie; Yuanfei Liu
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

Review 2.  Travelling with heart failure: risk assessment and practical recommendations.

Authors:  Stephan von Haehling; Christoph Birner; Elke Dworatzek; Stefan Frantz; Kristian Hellenkamp; Carsten W Israel; Tibor Kempf; Hermann H Klein; Christoph Knosalla; Ulrich Laufs; Philip Raake; Rolf Wachter; Gerd Hasenfuss
Journal:  Nat Rev Cardiol       Date:  2022-01-06       Impact factor: 49.421

Review 3.  Epidemiology and prevention of venous thromboembolism.

Authors:  Pamela L Lutsey; Neil A Zakai
Journal:  Nat Rev Cardiol       Date:  2022-10-18       Impact factor: 49.421

Review 4.  3D bioprinting of cardiac tissue: current challenges and perspectives.

Authors:  Brian Kato; Gary Wisser; Devendra K Agrawal; Tim Wood; Finosh G Thankam
Journal:  J Mater Sci Mater Med       Date:  2021-05-06       Impact factor: 3.896

5.  Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization.

Authors:  Pulkit Chaudhury; Paulino Alvarez; Madonna Michael; Marwan Saad; G Jay Bishop; Mazen Hanna; Venu Menon; Randall C Starling; Alex C Spyropoulos; Milind Desai; Amgad Mentias
Journal:  J Am Heart Assoc       Date:  2022-05-10       Impact factor: 6.106

Review 6.  Considerations for Heart Failure Care During the COVID-19 Pandemic.

Authors:  Ersilia M DeFilippis; Nosheen Reza; Elena Donald; Michael M Givertz; JoAnn Lindenfeld; Mariell Jessup
Journal:  JACC Heart Fail       Date:  2020-06-03       Impact factor: 12.035

7.  The effect of deep vein thrombosis on major adverse limb events in diabetic patients: a nationwide retrospective cohort study.

Authors:  Po-Chang Wang; Tien-Hsing Chen; Chang-Min Chung; Mei-Yen Chen; Jung-Jung Chang; Yu-Sheng Lin; Pao-Hsien Chu; Yun-Shing Peng; Ming-Shyan Lin
Journal:  Sci Rep       Date:  2021-04-13       Impact factor: 4.379

8.  Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy.

Authors:  Yiheng Pan; Pamela B Davis; David C Kaebler; Robert P Blankfield; Rong Xu
Journal:  Cardiovasc Diabetol       Date:  2022-09-01       Impact factor: 8.949

9.  Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism.

Authors:  Slobodan Obradovic; Boris Dzudovic; Bojana Subotic; Jovan Matijasevic; Zorica Mladenovic; Aleksandar Bokan; Jadranka Trobok; Sandra Pekovic; Sonja Salinger-Martinovic; Ljiljana Jovanovic; Ljiljana Kos; Tamara Kovacevic-Preradovic; Maja Nikolic; Vladimir Miloradovic; Ana Kovacevic-Kuzmanovic; Nenad Zec; Natasa Markovic-Nikolic; Ilija Srdanovic; Zoran Gluvic; Srdjan Kafedzic; Sasa Pancevacki; Aleksandar Neskovic; Stavros Konstantinides
Journal:  ESC Heart Fail       Date:  2020-09-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.